Analysts rate Raia Drogasil S.A. Buy (bullish), based on 15 analysts. Average price target: R$25.97.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 6565 declarations
Raia Drogasil S.A., a Brazilian healthcare company listed on the B3 Brazilian exchange with a market capitalisation of BRL 37.8 billion, has the largest volume in this set: 6,565 filings published from December 1, 2018 to October 5, 2026, 5,764 of them of another kind, from only 4 filers, all published as Anonymous followed by their category. Anonymous (Controlador ou Vinculado) alone signs 6,124. The median publication delay is 26 days.
Sales number 510, 507 of them with an amount worth EUR 440.2 million (median EUR 214,250), against 226 purchases, 223 with an amount worth EUR 31.3 million (median EUR 53,315). The three largest sales come from Anonymous (Controlador ou Vinculado): EUR 32,761,124 on May 14, 2021, EUR 18,707,315 and EUR 15,099,360 on November 10, 2021. The same filer bought EUR 4,915,666 on June 24, 2026 and EUR 3,835,883 on August 7, 2026.
Anonymous (Diretor ou Vinculado) signs 374 filings, 113 purchases and 156 sales among them.
Volume has jumped: 584 filings in 2019, 118 in 2020, then 897 in 2023, 2,187 in 2024 and 1,894 in 2025. Over the last twelve months: 418 filings, 16 purchases, 29 sales. The 224 purchases with a 90-day result have a median of 12.6%, with 65% of results positive: recorded past results, not a forecast.
Purchases our model currently ranks for the recommendations list.
All recommendations